Biodexa Pharmaceuticals plc American Depositary Shs - BDRX STOCK NEWS

Biodexa Pharmaceuticals PLC announces a registered direct offering of US$3.32 million, with the aim of raising funds for working capital and general corporate purposes. The offering is expected to close on May 26, 2023.

Biodexa Pharmaceuticals has signed a non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, a precision oncology company. VarianBio is developing a high-potency aPKCi inhibitor for the treatment of various cancers. The proposed acquisition will involve the exchange of 10MM ADSs as initial consideration, with the potential for an additional 6MM ADSs based on milestones. Biodexa plans to raise at least US$7.0MM to fund VAR-101 through its Phase I proof-of-concept study.

Biodexa Pharmaceuticals PLC has announced the exercise of Pre-Funded Warrants leading to the issuance of 6,275,465 new ordinary shares at a price of US$0.0004 per warrant, effectively generating gross proceeds of US$502.04. This transaction relates to 1,255,093 Pre-Funded Warrants exercised on April 18, 2023. The new shares will be admitted for trading on the AIM of the London Stock Exchange around April 25, 2023. Post-admission, the company’s total ordinary shares will be 94,629,412, with the new shares ranking pari passu with existing ones. This adjustment serves as a numerator for shareholders calculating their interests under the FCA's regulations.

Biodexa Pharmaceuticals PLC has announced the issuance of 11,001,255 new ordinary shares at £0.02 each, resulting from the exercise of 2,200,251 Pre-Funded Warrants on 6 April 2023. The shares will commence trading on AIM by approximately 8.00 a.m. on 17 April 2023. Following this issuance, the company's total issued share capital will be 88,353,947 ordinary shares, each with voting rights. This increase may influence shareholder calculations for interest notifications under the FCA's rules. The announcement contains forward-looking statements and highlights the company's focus on improving drug delivery technologies and its proprietary platforms. Further details are available in the company's circular dated 7 March 2023.

Biodexa Pharmaceuticals PLC (AIM:BDRX; NASDAQ:BDRX) announced the issuance of 24,798,160 new ordinary shares following the exercise of Pre-Funded Warrants.

Of the exercised warrants, 3,026,538 were net exercised cashlessly, while 1,933,093 were exercised for US$773.24. The total issued share capital will increase to 65,793,047 shares with voting rights post-admission on April 12, 2023.

These new shares will rank pari passu with existing shares, impacting shareholder calculations regarding interests in the company.

Biodexa Pharmaceuticals PLC has issued an additional 10,508,394 Pre-Funded Warrants, increasing the total to 12,444,558 under its Private Placement. The issuance follows a calculation based on 90% of the volume-weighted average prices from the preceding five trading days. Each warrant is immediately exercisable into one new ADS (equivalent to five new Ordinary Shares) at an exercise price of US$0.0004. The announcement is tied to a previously disclosed consolidation and ratio change.

Biodexa Pharmaceuticals PLC (AIM:BDRX; Nasdaq:BDRX) announced the issuance of 7,473,095 new ordinary shares following the exercise of 848,068 A Warrants and 646,551 B Warrants on a cashless basis. This transaction will increase the company's issued share capital to 16,140,432 ordinary shares, effective April 3, 2023. The new shares will rank pari passu with existing shares and serve as the denominator for shareholders to assess any changes in their interest. This move may influence shareholder stakes, but no treasury shares are held by the company.